Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
Company Directory
Sorin
via Benigno Crespi 17
Milano 20159
Italy
[t] 0039-02-69969711-509
The Sorin Group is a world leader in the development of medical technologies for cardiac surgery, offers innovative therapies for cardiac rhythm dysfunctions, interventional cardiology and the treatment of chronic kidney diseases.

The Sorin Group features the following brands: Dideco, CarboMedics, COBE Cardiovascular, Stockert, Mitroflow, ELA Medical, Sorin Biomedica, Bellco and Bellco-Soludia.

At the Sorin Group 4,500 employees serve over 5,000 public and private treatment centres in more than 80 countries.
Aortic root surgery system used on first European patient
11 November, 2013
A European implant of Mitroflow Valsalva Conduit has been performed as an innovative approach to aortic root surgery for the first time
Sorin Group gains FDA 510(K) clearance for perfusion charting system
31 July, 2013
Sorin Group receives 510(k) clearance for commercialization of Sorin CONNECT, Sorin Group's new innovative and intuitive perfusion electronic charting system.
Sorin signs supply agreement for Boston Scientific's Lotus valve system
16 July, 2013
Sorin signs a supply agreement for the manufacturing of certain components of the Lotus Aortic Valve System, Boston Scientific's second-generation TAVR (Transcatheter Aortic Valve Replacement) technology.
Clinical study validates pacemakers for sleep apnea monitoring against polysomnography
25 June, 2013
Sorin Group reveals the results of the DREAM clinical trial.
First US implant of CRT-D system is implemented for RESPOND CRT IDE clinical trial
24 June, 2013
Sorin Group announces the first US implant of the company's PARADYM SonR CRT System for the RESPOND CRT IDE Clinical Trial.
Sorin Group launches family of pacemakers with sleep apnea monitoring
20 June, 2013
Sorin Group receives CE mark approval and the European commercial launch of the REPLY 200 family of pacemakers featuring Sleep Apnea Monitoring (SAM).
Sorin Group receives FDA approval for remote monitoring solution for patients with ICDs
13 May, 2013
Sorin Group receives FDA approval for the SMARTVIEW remote monitoring solution for patients with implanted cardiac rhythm management (CRM) devices and the company is beginning the US launch of the device.
Sorin receives conditional FDA approval to conduct IDE clinical trial for sutureless aortic valve in the USA
30 April, 2013
Sorin Group receives US Food and Drug Administration (FDA) approval of the company's Investigational Device Exemption (IDE) application and clinical trial protocol to begin evaluating its PERCEVAL S sutureless aortic tissue valve.
Sorin gains conditional FDA approval to conduct clinical trial using heart failure management technology
22 March, 2013
Sorin Group receives US Food and Drug Administration (FDA) conditional approval for the company's Investigational Device Exemption (IDE) application and clinical trial protocol for RESPOND CRT.
Sorin Group completes further investment in Enopace Biomedical
04 March, 2013
Sorin Group makes an additional minority investment linked with an option-to-buy in Enopace Biomedical, an early-stage company focused on the development of a neuromodulation system to treat patients with Heart Failure.
Sorin Group acquires Alcard of Brazil
20 February, 2013
Sorin Group acquires Alcard Industria Mecanica, a leading Brazilian manufacturer of medical devices for cardiac surgery.
Sorin Group achieves first PARADYM RF implant in North America
07 December, 2012
Sorin Group reports the first implant of PARADYM RF in Canada at the Montreal Heart Institute.
Sorin Group receives Japanese PMDA approval of aortic pericardial heart valve
06 December, 2012
Sorin Group receives the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) approval for the company's Mitroflow Aortic Pericardial Heart Valve.
Sorin Group acquires Neurotech to accelerate neurostimulation plans
14 November, 2012
Sorin Group is acquiring Neurotech, a developer of neurostimulation devices.
New heart device enables simultaneous implantation of an aortic tissue valve and ascending aorta
08 November, 2012
Sorin Group launching the Mitroflow Valsalva Conduit in the USA, which claims to be the only Valsalva conduit graft approved by the US Food and Drug Administration (FDA) for use in combination with an aortic tissue valve.
World's smallest pacemakers feature algorithms to improve patient safety
14 September, 2012
Sorin Group receives marketing approval from China's State Food and Drug Administration (SFDA) and full commercial launch in China of the REPLY and ESPRIT families of pacemakers.
Sorin Group invests in Cardiosolutions to develop mitral valve technology
10 July, 2012
Sorin Group is making a minority investment in Cardiosolutions, an early-stage company focused on the development of an innovative percutaneous system to treat patients with moderate to severe mitral valve regurgitation.
Sorin Group acquires California Medical Laboratories (CalMed)
03 July, 2012
Sorin Group is acquiring California Medical Laboratories, a manufacturer of high quality cardiovascular cannulae, for $14 million.
Sorin deploys Camstar enterprise platform to drive quality improvements
18 June, 2012
The Sorin Group, a global medical device company and a leader in the treatment of cardiovascular diseases, is deploying Camstar Systems' Camstar Enterprise Platform to support its global growth and continuous improvement initiatives.
Sorin and Orange Business Services launches CRM remote monitor
15 June, 2012
Sorin Group and Orange Business Services, a leading global communications solutions integrator, are launching SMARTVIEW, a remote monitoring solution for patients with implanted cardiac rhythm management(CRM) devices in several countries in Europe.
Sorin starts enrollment in the dream clinical study
14 June, 2012
Sorin Group is reporting the first patient enrolment in the DREAM clinical trial which is a study is to evaluate sensitivity and positive predictive value of Sleep Apnea Monitoring (SAM) in pacemaker patients, compared to polysomnography, the gold standard test to diagnose sleep apnea disorders.
Sorin receives regulatory approval to market annuloplasty ring in Japan
18 May, 2012
Sorin Group receives authorization from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to market its MEMO 3D Semi-Rigid Annuloplasty Ring.
Sorin launches new portfolio of pacing and defibrillation leads
02 February, 2012
Sorin Group receives CE Mark approval and commercial launch for a comprehensive new range of pacing, defibrillation and left ventricular leads. Designed for safety and long term reliability, TILDA pacing leads, VIGILA defibrillation leads and CELERITY left ventricular lead families offer multiple implant options to accommodate patients' needs and physicians' preferences.
Sorin's ISIS-ICD clinical trial enrolls first patient
24 October, 2011
Sorin Group is reporting the first patient enrollment in the company's ISIS-ICD clinical trial.
Sorin Group invests in Enopace Biomedical
19 October, 2011
Sorin Group is making a minority investment in Enopace Biomedical, an early-stage company focused on the development of a neuromodulation system to treat patients with congestive heart failure.
Sorin launches next-generation autotransfusion device in the USA
04 May, 2011
Sorin Group is launching in the USA the company’s next-generation of Sorin’s autotransfusion (ATS) device family, XTRA.
Sorin invests in new medical technology incubator in Europe
28 February, 2011
Sorin Group is making a minority investment in MD Start, the first venture capital and industry-backed medical technology incubator in Europe.
Sorin passes major implant milestone for aortic pericardial heart valves
23 February, 2011
Sorin Group reaches a major milestone with more than 100,000 of the company’s Mitroflow Aortic Pericardial Heart Valves having now been implanted worldwide.
Sorin Group acquires Gish Biomedical from private equity group
10 June, 2010
Sorin Group acquires Gish Biomedical from Ventizz Capital Partners, a private equity group focused on technology-oriented companies.
Sorin partners CardioMedical for minimally invasive cardiac surgery instruments
05 May, 2010
Sorin Group enters into a distribution agreement with CardioMedical, making Sorin Group, CardioMedical’s selected partner for the entire Cardio Vision MIS Portfolio which is a comprehensive catalogue of minimally invasive cardiac surgery instruments and accessories.
New generation Heart-Lung Machine receives US FDA clearance
22 February, 2010
The US Food and Drug Administration gives clearance for Sorin’s newest generation C5 Heart-Lung Machine (HLM).
Sorin cardiac resynchronization therapy defibrillator completes first implant
09 February, 2010
Sorin Group receives US FDA approval and completes first implant of its next-generation of cardiac resynchronization therapy defibrillator (CRT-D), Paradym CRT Model 8750.
Sorin reports first inclusion in the Clepsydra clinical trial
04 December, 2009
Sorin Group reports the first inclusion of a patient in the Clepsydra clinical trial which will investigate the sensitivity to changes in heart failure status of PhD, a diagnostic feature using the dual sensor technology of minute ventilation and accelerometer to monitor patient’s breathing and activity levels every day.
Sorin and Orange clinch major award for innovative remote monitoring solution
02 December, 2009
Orange Business Services and Sorin Group are named ′Best Change-Maker’ at this year’s annual World Communication Awards (WCA) for their innovative work in the development of a remote monitoring solution for cardiac patients.
Sorin receives Health Canada TPD approval for REPLY family of pacemakers
10 July, 2009
Sorin Group receives the Health Canada Therapeutic Products Directorate (TPD) approval to market the REPLY family of dual and single chamber rate adaptive pacemakers.
Sorin pacemaker duo receive approval to launch in Japan
06 July, 2009
Japan’s Ministry of Health, Labor and Welfare (MHLW) gives approval to market the Facil and Reply families of dual and single chamber rate responsive pacemakers.
Sorin passes 1000th heart-lung machine milestone
29 June, 2009
Sorin Group delivers its 1000th S5 Heart-Lung Machine with a contract to supply the Mount Sinai Medical Center, one of the world’s leading centres for cardiovascular medicine, based in New York, USA.
Sorin releases new generation dual chamber ICD
25 June, 2009
Sorin Group announces the release and first implant of its new generation Paradym DR 8550 dual chamber implantable cardioverter-defibrillator (ICD).
Sorin signs up JLL to distribute tissue heart valve in Japan
20 April, 2009
Sorin Group is entering into a long-term exclusive distribution agreement with Japan Lifeline (JLL), a leading distributor of medical devices in Japan.
Sorin releases ESPRIT pacemaker family to Europe
07 April, 2009
Sorin Group receives CE mark certification releases the ESPRIT pacemaker family to the market in Europe.
Sorin and Orange collaborate to develop remote monitoring of CRM devices
20 March, 2009
Sorin Group together with Orange Business Services, the leading global communications solutions integrator, are planning to develop and service a remote monitoring solution for patients implanted with cardiac rhythm management (CRM) devices.
Sorin begins sutureless aortic heart valve clinical trial in Paris
26 February, 2009
Sorin Group has enrolled the first three patients in a clinical trial aimed at obtaining European market approval for the company’s ′Perceval S’ Sutureless Aortic Heart Valve.
Sorin acquires Clearglide endoscopic vessel harvesting range
13 February, 2009
Sorin Group has acquired the Clearglide endoscopic vessel harvesting product line of Datascope. Endoscopic vessel harvesting (′EVH’) devices enable less-invasive harvesting of vessels for use in coronary artery bypass grafting.
Sorin sells off renal care business to European investment consortium
02 January, 2009
Sorin Group has completed the divestment of its Renal Care Business to an investment consortium led by Argos Soditic, an independent European private equity firm, and MPS Venture SGR, on behalf of the closed-end fund ′Emilia Venture’.
Sorin's Isoline defibrillation leads receive approval fro Japanese authorities
12 December, 2008
Sorin Group has received Japanese approval for its Isoline defibrillation leads which are now released to the Japanese market.
Sorin plans to acquire Datascope's endoscopic vessel harvesting product range
28 November, 2008
Sorin Group has entered into a binding asset purchase agreement to purchase the Clearglide endoscopic vessel harvesting product range from Datascope.
Sorin releases new generation CRT-D, completes first implant
27 November, 2008
Sorin Group has released its new-generation Paradym CRT 8750 cardiac resynchronization therapy defibrillator (CRT-D) and completed the device's first implant.
Sorin to apply Sphere Medical’s microsensor for cardiopulmonary bypass operations
19 November, 2008
Sorin Group has signed an agreement to apply Sphere Medical’s proprietary microsensor technology in the field of cardiopulmonary bypass.
Sorin receives offer to purchase its renal care business
13 October, 2008
Sorin Group has received an offer for the acquisition of its renal care business and the group has granted exclusivity to an investment consortium led by Argos Soditic, an independent European private equity firm, and MPS Venture SGR, for the purpose of finalising negotiations.
Sorin enrols first patient in e-Optima Drug-Eluting Stent registry
23 September, 2008
Sorin Group has announced the first patient enrolment in the e-Optima registry which is designed to assess the clinical performance of the Sorin Group Optima Drug-Eluting Stent (DES) Carbostent in the treatment of real-world patients in routine clinical practice.
First | Prev  | 1 | 2  | Next  | Last
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo